Abbott Laboratories (ABT) : First Financial Bank N.a. – Trust Division scooped up 18,150 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 11, 2016. The investment management firm now holds a total of 156,392 shares of Abbott Laboratories which is valued at $6,803,052.Abbott Laboratories makes up approximately 1.26% of First Financial Bank N.a. – Trust Division’s portfolio.
Other Hedge Funds, Including , Gradient Investments reduced its stake in ABT by selling 109,203 shares or 97.94% in the most recent quarter. The Hedge Fund company now holds 2,296 shares of ABT which is valued at $99,876. Abbott Laboratories makes up approx 0.01% of Gradient Investments’s portfolio.Exxonmobil Investment Management Inc Tx reduced its stake in ABT by selling 4,948 shares or 1.3% in the most recent quarter. The Hedge Fund company now holds 375,342 shares of ABT which is valued at $16,128,446. Abbott Laboratories makes up approx 0.34% of Exxonmobil Investment Management Inc Tx’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in ABT by selling 131,464 shares or 31.19% in the most recent quarter. The Hedge Fund company now holds 290,060 shares of ABT which is valued at $12,397,164. Abbott Laboratories makes up approx 0.05% of Bnp Paribas Arbitrage Sa’s portfolio.Lynch Associatesin boosted its stake in ABT in the latest quarter, The investment management firm added 5,055 additional shares and now holds a total of 52,281 shares of Abbott Laboratories which is valued at $2,234,490. Abbott Laboratories makes up approx 0.99% of Lynch Associatesin’s portfolio.Beacon Financial Group boosted its stake in ABT in the latest quarter, The investment management firm added 2,203 additional shares and now holds a total of 16,831 shares of Abbott Laboratories which is valued at $719,357. Abbott Laboratories makes up approx 0.15% of Beacon Financial Group’s portfolio.
Abbott Laboratories closed down -2.34 points or -5.38% at $41.16 with 2,38,96,101 shares getting traded on Tuesday. Post opening the session at $43.2, the shares hit an intraday low of $41.02 and an intraday high of $43.27 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.